NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
SBI Raises USD 250 Million via Senior Unsecured Floating Rate Bonds
State Bank of India (SBI) has successfully concluded the issuance of USD 250 million in Senior Unsecured Floating Rate Notes. These bonds are issued through the bank's London branch with a short-term maturity of 12 months. The coupon is set at Overnight SOFR plus 50 basis points per annum, payable quarterly. This issuance reflects the bank's ability to access international capital markets for liquidity management at competitive pricing.
முக்கிய அம்சங்கள்
Successfully raised USD 250 million through Senior Unsecured Floating Rate CMU Cleared NotesShort-term maturity of 12 months with a coupon of O/N SOFR + 50 bpsBonds issued through the London branch under Regulation-S frameworkInterest payments scheduled quarterly in arrears starting from February 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine but positive liquidity management step that confirms SBI's strong standing in global credit markets. No immediate change in investment strategy is required based on this fundraise alone.
SBI Life 9M FY26 Results: VoNB Up 17% to ₹50.4 Billion, APE Grows 16%
SBI Life reported a steady performance for 9M FY26, with Annualized Premium Equivalent (APE) growing 16% YoY to ₹185.2 billion. The Value of New Business (VoNB) increased by 17% to ₹50.4 billion, supported by a slight expansion in margins to 27.2%. While Profit After Tax (PAT) saw a modest 4% growth to ₹16.7 billion, the Indian Embedded Value (IEV) rose significantly by 18% to ₹801.3 billion. The company maintained its private market leadership with a 25.6% share in Individual Rated Premium.
முக்கிய அம்சங்கள்
Value of New Business (VoNB) grew 17% YoY to ₹50.4 billion with margins improving to 27.2%Annualized Premium Equivalent (APE) reached ₹185.2 billion, marking a 16% YoY growthAssets Under Management (AUM) crossed the ₹5.1 trillion mark, up 16% YoY13th-month persistency improved by 101 bps to 87.1%, indicating better customer retentionIndian Embedded Value (IEV) stands at ₹801.3 billion, reflecting 18% YoY growth
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong growth in VoNB and IEV, which are key long-term value drivers for life insurers. While the cost ratio increased slightly to 11.2%, the company's market leadership and margin stability remain positive indicators.
SBI Life Q3 FY26 PAT Rises 4.7% YoY to ₹577 Cr; Gross Premium Up 22%
SBI Life reported a steady performance for Q3 FY26, with Gross Premium Income growing 21.8% year-on-year to ₹30,245 crore. Net profit saw a modest increase of 4.7%, reaching ₹577 crore compared to ₹551 crore in the same quarter last year. The company maintained a healthy solvency ratio of 1.91, well above the regulatory threshold of 1.50. While operating expenses increased, the 13th-month persistency ratio improved to 83.99%, indicating better customer retention.
முக்கிய அம்சங்கள்
Gross Premium Income grew by 21.8% YoY to ₹30,245 crore in Q3 FY26.Net Profit (PAT) increased by 4.7% YoY to ₹577 crore for the quarter.Solvency ratio remains robust at 1.91, though down from 2.04 a year ago.13th-month persistency ratio improved to 83.99% from 82.67% YoY.Operating expense ratio increased to 11.56% compared to 9.67% in the previous year's quarter.
👀 கவனிக்க வேண்டியவை
Investors should focus on the strong top-line growth and improving persistency, which are positive long-term indicators. The stock remains a solid play in the insurance sector, though rising expense ratios warrant monitoring.
NBIFIN Proposes Business Expansion and Appoints Hari Mohan & Prashant Bangur to Board
N. B. I. Industrial Finance Co. Ltd. is seeking shareholder approval via postal ballot to significantly expand its business objects beyond traditional finance. The company intends to diversify into trading commodities, merchandise, and information technology services. Key leadership changes include the appointment of Mr. Hari Mohan Bangur and Mr. Prashant Bangur as Non-Executive Directors. The authorized share capital is confirmed at ₹10.35 crore, with the e-voting period concluding on March 4, 2026.
முக்கிய அம்சங்கள்
Expansion of Memorandum of Association to include trading in commodities, IT services, and software development.Appointment of Mr. Hari Mohan Bangur and Mr. Prashant Bangur as Non-Executive Non-Independent Directors.Authorized Share Capital defined at ₹10.35 crore, divided into 2.07 crore equity shares of ₹5 each.E-voting period scheduled from February 3, 2026, to March 4, 2026.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's transition into diversified trading and IT sectors as it moves away from a pure investment firm model. The induction of the Bangur family members into the board suggests a strategic shift that could drive future growth.
SBI: Shri Ashwini Kumar Tewari Assumes Charge as Managing Director
State Bank of India (SBI) has announced that Shri Ashwini Kumar Tewari has officially assumed the role of Managing Director effective January 28, 2026. This follows the Government of India notification dated December 16, 2025, regarding his re-appointment to the position. The move ensures continuity in the bank's top leadership team, which is crucial for India's largest public sector lender. Investors typically view leadership stability at the MD level as a positive sign for long-term strategic execution.
முக்கிய அம்சங்கள்
Shri Ashwini Kumar Tewari assumed the post of Managing Director on January 28, 2026The appointment follows the Government of India Notification No. 2/1/2025-BO.I dated December 16, 2025Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015The re-appointment ensures leadership continuity within the bank's executive management team
👀 கவனிக்க வேண்டியவை
No immediate action is required as this is a planned re-appointment ensuring leadership stability. Investors should remain focused on the bank's upcoming quarterly results and credit growth trends.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
S&P Global Upgrades Biocon Biologics Rating to 'BB+'; Outlook Revised to Stable
S&P Global has upgraded Biocon Biologics' credit rating to 'BB+' from 'BB' following a significant reduction in the company's adjusted debt. This upgrade follows the settlement of a $1 billion CCPS liability to Viatris through a mix of equity and cash, simplifying the capital structure. Adjusted debt is projected to fall to INR 115 billion by FY26 from INR 248 billion in FY25, significantly improving the company's financial health. Analysts expect EBITDA to grow to INR 45 billion by FY27, driven by a 15% growth in the biosimilars segment.
முக்கிய அம்சங்கள்
Credit rating upgraded to 'BB+' from 'BB' with a 'Stable' outlook by S&P Global.Adjusted debt forecasted to decline to INR 115 billion by FY26, down from INR 248 billion in FY25.FFO-to-debt ratio expected to improve from under 10% in FY25 to 30% by FY27.Settled $1 billion CCPS to Viatris using $460 million in fresh equity and share swaps.EBITDA projected to reach INR 45 billion by FY27 with steady margins of 22-23%.
👀 கவனிக்க வேண்டியவை
This upgrade marks a critical de-risking milestone for Biocon as it successfully manages the high leverage from the Viatris acquisition. Investors should monitor the execution of new biosimilar launches like bStelara and Aflibercept as primary drivers for future valuation re-rating.
Bikaji Q3 FY26: PAT Surges 122.3% YoY to ₹622 Mn; EBITDA Margins Expand to 12.5%
Bikaji Foods reported a robust Q3 FY26 with revenue growing 10.7% YoY to ₹7,900 mn, supported by an 8.4% underlying volume growth. The company saw a massive expansion in profitability, with EBITDA surging 77.1% YoY to ₹984 mn and PAT rising 122.3% to ₹622 mn. Gross margins improved significantly by 586 bps YoY to 34.7%, driven by a favorable product mix and operational efficiencies. For the nine-month period (9M FY26), revenue and PAT grew by 13.3% and 28.7% respectively, demonstrating consistent performance across its core ethnic snacks segment.
முக்கிய அம்சங்கள்
Revenue from operations increased 10.7% YoY to ₹7,900 mn with 8.4% volume growth.EBITDA margins expanded by 466 bps YoY to 12.5%, with absolute EBITDA at ₹984 mn.Net Profit (PAT) grew by 122.3% YoY to ₹622 mn for the quarter ended December 2025.Export revenue witnessed a strong growth of 39.1% YoY, contributing 5.6% to the total mix.Direct distribution reach increased to 3.34 lakh outlets, part of a total reach of 13.93 lakh outlets.
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and triple-digit PAT growth, which indicates strong pricing power and cost management. The company's aggressive regional marketing and expansion of direct reach provide a positive outlook for long-term volume growth.
Bikaji Foods Approves ₹50Cr Retail Investment and JV for Frozen Bakery Business
Bikaji Foods has announced a major strategic expansion involving a ₹50 Crore capital infusion into its retail subsidiary to scale QSR, café, and travel catering formats. The company is also entering the high-growth frozen bakery segment through a 70:30 joint venture with the founder of 'Bakemart'. Additionally, it is investing ₹25 Crore in Jai Barbareek Dev Snacks via convertible debentures and providing ₹13 Crore in loans to manufacturing partners. These moves signal a significant shift towards becoming a diversified food services player beyond traditional snacks.
முக்கிய அம்சங்கள்
Approved ₹50 Crore additional investment in Bikaji Foods Retail Limited for QSR and café expansion.Formed a 70:30 Joint Venture with Bakemart founder to enter the frozen bakery market in India.Authorized ₹25 Crore investment in Jai Barbareek Dev Snacks via 2.5 Crore Optionally Convertible Debentures.Approved loans of ₹5 Crore to subsidiary Petunt Food and ₹8 Crore to contract unit Dadiji Snacks.Retail expansion targets diverse formats including mobile food stations, kiosks, and food chains.
👀 கவனிக்க வேண்டியவை
Investors should view these strategic investments as a positive move toward higher-margin retail and bakery segments. Monitor the execution of the QSR rollout and the scaling of the frozen bakery JV as key growth drivers.
Bikaji Q3 Net Profit Jumps 114% YoY to ₹64.7 Cr; Board Approves ₹50 Cr Subsidiary Investment
Bikaji Foods reported a strong year-on-year performance for Q3 FY26, with standalone net profit surging 113.9% to ₹64.7 crore. Revenue from operations grew 8.6% YoY to ₹716.5 crore, although it saw a sequential decline from Q2. The board approved significant strategic moves, including a ₹50 crore investment in its retail subsidiary and a new joint venture for the frozen and bakery segment with the founder of 'Bakemart'. Additionally, the company is expanding its manufacturing reach through a ₹25 crore investment in Jai Barbareek Dev Snacks via convertible debentures.
முக்கிய அம்சங்கள்
Standalone Net Profit for Q3 FY26 rose 113.9% YoY to ₹64.7 crore from ₹30.2 crore.Revenue from operations increased 8.6% YoY to ₹716.5 crore, while 9M FY26 revenue reached ₹2,104.9 crore.Approved ₹50 crore additional capital infusion into Bikaji Foods Retail Limited to support expansion.Entered a Joint Venture with 'Bakemart' founder to enter the frozen and bakery business in India via Bikaji Bakes Private Limited.Authorized ₹25 crore investment in Jai Barbareek Dev Snacks via Optionally Convertible Debentures (OCDs).
👀 கவனிக்க வேண்டியவை
Investors should view the strong YoY profit growth and the strategic entry into the high-margin frozen/bakery segment as long-term growth drivers. Monitor the execution of the new JV and the impact of the retail subsidiary investment on overall consolidated margins.
NBIFIN Appoints Shree Cement Promoters to Board and Diversifies Business Objects
N. B. I. Industrial Finance (NBIFIN) has appointed Mr. Hari Mohan Bangur and Mr. Prashant Bangur, prominent leaders from Shree Cement, as Additional Directors. The company is significantly expanding its business scope via MOA amendments to include commodities trading, IT services, and data processing. The authorized share capital is established at ₹10.35 crore, divided into 2.07 crore shares of ₹5 each. These changes, along with the Q3 FY26 results approval, signal a potential strategic pivot for the investment firm.
முக்கிய அம்சங்கள்
Appointment of Shree Cement's Hari Mohan Bangur and Prashant Bangur to the Board of Directors.MOA amended to allow entry into IT services, e-commerce, and diverse commodity trading across India and abroad.Authorised Share Capital defined as ₹10.35 crore, consisting of 2.07 crore equity shares at ₹5 each.Resignation of Non-Executive Director Ms. Riya Puja Jain effective January 27, 2026.Board approved Unaudited Standalone and Consolidated Financial Results for the quarter ended December 31, 2025.
👀 கவனிக்க வேண்டியவை
The entry of top-tier leadership from Shree Cement is a major positive signal; investors should monitor the company's execution in its newly added business verticals like IT and commodities.
IFB Industries Appoints Industry Veterans from HCL and Exide to Board
IFB Industries has announced a significant board reconstitution, appointing Mr. Saurav Adhikari (former HCL leader) and Mr. Subir Chakraborty (former MD of Exide Industries) as Independent Directors for two-year terms. Ms. Sreedevi Pillai has been re-appointed as an Independent Director for a second five-year term, while Mr. Ashok Bhandari transitions to a Non-Independent Director role. The company also appointed Mani & Co. as Cost Auditors for FY 2025-26 with a proposed remuneration of ₹ 9 lakhs. These changes include the full reconstitution of five key board committees, including Audit and Risk Management.
முக்கிய அம்சங்கள்
Appointment of Mr. Saurav Adhikari (ex-HCL) and Mr. Subir Chakraborty (ex-Exide MD) as Independent Directors for 2 years.Re-appointment of Ms. Sreedevi Pillai as Independent Director for a second 5-year term starting January 28, 2026.Transition of Mr. Ashok Bhandari to Non-Executive, Non-Independent Director for 2 years starting January 30, 2026.Appointment of Mani & Co. as Cost Auditors for FY 2025-26 at a remuneration of ₹ 9 lakhs.Reconstitution of five major board committees including Audit, CSR, and Risk Management.
👀 கவனிக்க வேண்டியவை
The induction of high-profile veterans from HCL and Exide Industries is a positive signal for corporate governance and strategic oversight. Investors should view this as a strengthening of the leadership team, though immediate operational impact may be limited.
IFB Industries Reports Financial Results for Quarter Ended December 31, 2025
IFB Industries Limited has officially submitted its financial results for the third quarter and nine-month period ended December 31, 2025. The Board of Directors approved these results during their meeting held on January 24, 2026. This announcement is a routine regulatory filing that provides a snapshot of the company's performance during the fiscal year. Investors should now look for the detailed line-item breakdown to evaluate the company's profitability and revenue growth.
முக்கிய அம்சங்கள்
Board of Directors approved the financial results on January 24, 2026The reporting period covers the quarter and nine months ending December 31, 2025Submission made to the stock exchanges in compliance with SEBI listing regulations
👀 கவனிக்க வேண்டியவை
Investors should review the full financial statement to analyze segmental performance in Home Appliances and Engineering. Monitor the operating margins and debt-to-equity ratio for signs of fiscal improvement.
Hester Biosciences Receives Manufacturing License for H9N2 Avian Influenza Vaccine
Hester Biosciences has received a manufacturing license from the Food & Drugs Control Administration for its Low Pathogenic Avian Influenza (H9N2) vaccine for poultry. The H9N2 strain is a persistent challenge in the poultry industry, causing significant economic losses through reduced egg production and broiler performance. This vaccine was developed using technology acquired from ICAR-NIHSAD via Agrinnovate India. This regulatory milestone strengthens Hester's poultry healthcare portfolio and addresses a year-round comorbidity issue in the sector.
முக்கிய அம்சங்கள்
Received manufacturing and marketing license from FDCA for Inactivated Avian Influenza H9N2 vaccine.Technology for the vaccine was acquired from ICAR-NIHSAD through Agrinnovate India.Targets the H9N2 strain which causes significant economic losses in both layer and broiler poultry segments.The vaccine aims to prevent irreversible drops in egg production and high mortality rates associated with the virus.Strengthens the company's prevention-led poultry healthcare product pipeline.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that expands Hester's product offerings in the animal healthcare market. Monitor the commercial launch timeline and the subsequent impact on the poultry segment's revenue growth.
SBIN to Announce Q3FY26 Results and Host Analyst Meet on February 7, 2026
State Bank of India (SBIN) has scheduled its Central Board meeting for February 7, 2026, to consider and approve the financial results for the quarter ended December 31, 2025. Following the board meeting, the bank will conduct an analyst meet at 5:00 PM at the State Bank Bhavan Auditorium. The trading window for the bank's securities has been closed since January 1, 2026, and will remain closed until 48 hours after the results are declared. This is a routine but critical update for investors to gauge the performance of India's largest public sector bank.
முக்கிய அம்சங்கள்
Board meeting scheduled for February 7, 2026, to approve Q3FY26 financial results.Analyst and Institutional Investor meet to be held at 5:00 PM on the same day.Trading window for designated persons closed from January 1, 2026, to February 9, 2026.Results pertain to the third quarter of the financial year 2025-26 ending December 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the bank's asset quality and Net Interest Margin (NIM) trends when results are released on February 7. No immediate action is required as this is a routine pre-earnings notification.
Birla Corp Wins Legal Round; Court Rejects Stay on Amended Articles of Association
Birla Corporation has received a favorable ruling from the court regarding the amendment of its Articles of Association (AoA). The court rejected interim applications filed on January 17, 2026, which sought to restrain the company from implementing the amended AoA approved during the 105th AGM. This follows a December 2025 order where the Calcutta High Court dismissed challenges by five promoter shareholders. While the final outcome depends on pending miscellaneous appeals, the rejection of the stay allows the company to proceed with the implementation steps for now.
முக்கிய அம்சங்கள்
Court rejected interim applications filed on January 17, 2026, to stay the implementation of amended Articles of Association.The dispute involves Agenda Item No. 5 from the 105th Annual General Meeting notice regarding corporate governance changes.Previous orders on December 22, 2025, dismissed two Civil Revisional Applications filed by 5 promoter shareholders.The company received the formal court order on January 23, 2026, allowing them to move forward with the voting results.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final resolution of the miscellaneous appeals as they will determine the permanent status of the AoA amendments. The current ruling is a positive development that reduces immediate legal hurdles for the company's governance plans.
Biocon Completes BBL Stake Buy from Mylan for USD 200 Million; Holds ~98% Stake
Biocon Limited has completed the acquisition of the final tranche of 7,18,34,691 equity shares of Biocon Biologics Limited (BBL) from Mylan Inc. for USD 200 million. This follows the first tranche completed earlier in January 2026, bringing the total acquisition to 14,36,69,382 shares for a total cash consideration of USD 400 million. Post-acquisition, Biocon's ownership in its material subsidiary BBL has increased to approximately 98% on a fully diluted basis. This consolidation allows Biocon to have near-total control over its biologics business operations and future cash flows.
முக்கிய அம்சங்கள்
Acquired final 7,18,34,691 shares of Biocon Biologics Limited from Mylan Inc.Cash consideration for the final tranche amounted to USD 200 million.Total acquisition cost for 14.36 crore shares stands at USD 400 million.Biocon now holds ~98% of BBL's paid-up equity share capital on a fully diluted basis.
👀 கவனிக்க வேண்டியவை
Positive for long-term investors as it consolidates ownership in the high-growth biologics segment. Watch for the impact on the consolidated balance sheet and debt-to-equity ratio following the cash outflow.
MobiKwik Shareholders Approve Appointment of Radhakrishna Nair as Independent Director
One MobiKwik Systems Limited has announced the successful passing of a special resolution to appoint Mr. Radhakrishna Nair as a Non-Executive Independent Director. The resolution was passed via postal ballot with an overwhelming majority of 99.97% votes in favor. A total of 39.35 million votes were polled, representing approximately 50.03% of the total shareholding. This appointment is part of the company's efforts to strengthen its board governance and independent oversight.
முக்கிய அம்சங்கள்
Special resolution for appointment of Radhakrishna Nair passed with 99.9784% majorityTotal votes polled were 39,356,833 out of a total 78,658,458 shares (50.03% turnout)Promoter group and Public Institutions voted 100% in favor of the appointmentOnly 8,506 votes (0.0216%) were cast against the resolution by public non-institutional shareholdersThe company had 179,851 shareholders on the record date of December 19, 2025
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive step toward robust corporate governance. No immediate portfolio action is required based on this board-level appointment.
Bigbloc Q3 FY26 Revenue Up 28% YoY to ₹728 Million; Returns to Profitability
Bigbloc Construction reported a strong Q3 FY26 with revenue growing 28.1% YoY to ₹728 million, driven by a 38% increase in sales volumes to 2,14,643 CBM. The company returned to profitability with a PAT of ₹4 million, recovering from a significant loss in the previous quarter (Q2 FY26). EBITDA margins improved sequentially to 11.1% from 2.8%, aided by higher capacity utilization and better operating leverage. Despite a challenging nine-month period showing a net loss of ₹77 million, the quarterly performance indicates a sharp operational turnaround.
முக்கிய அம்சங்கள்
Revenue from operations grew 28.1% YoY to ₹728 million, marking the company's highest-ever quarterly sales.EBITDA increased 31.8% YoY to ₹81 million, with margins expanding to 11.1% from 10.7% YoY.Sales volume reached 2,14,643 CBM, a 38% YoY growth, while overall capacity utilization rose to 67%.Company secured a major purchase order from Larsen & Toubro (L&T) for AAC blocks.Renewable energy contribution increased to 36% of total power consumption, up from 26% in Q1 FY26.
👀 கவனிக்க வேண்டியவை
Investors should note the strong sequential recovery in margins and the return to profitability after a weak first half of the year. The major order from L&T and the commencement of trial runs for the construction chemicals facility are key growth catalysts to watch.
Birla Cable CEO R. Sridharan Resigns Effective January 19, 2026
Birla Cable Limited has announced the resignation of Shri R. Sridharan from his positions as Manager and Chief Executive Officer (CEO). The resignation is effective from the close of business hours on January 19, 2026, and is attributed to personal reasons. Following this departure, he will also cease to be a Key Managerial Personnel (KMP) of the company. The board has acknowledged his long-standing association and contributions to the firm.
முக்கிய அம்சங்கள்
Shri R. Sridharan resigned as Manager and CEO effective January 19, 2026The resignation is cited as being due to personal reasonsHe ceases to be a Key Managerial Personnel (KMP) under Section 203 of the Companies ActThe company has not yet announced a successor for the CEO position
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's upcoming announcements regarding the appointment of a new CEO to ensure leadership continuity. The stock may experience short-term uncertainty until a clear succession plan is communicated.
IDBI Bank Q3 FY26 Net Profit at ₹1,935 Cr; Gross NPA Improves to 2.57%
IDBI Bank reported a marginal 1% YoY increase in Q3 FY26 net profit to ₹1,935 crore, while 9M FY26 profit surged 39% to ₹7,570 crore, aided by a stake sale in NSDL. Asset quality continues to be a strong point, with Gross NPA declining by 100 bps YoY to 2.57% and Net NPA remaining stable at 0.18%. Loan growth was healthy at 15% YoY, though Net Interest Margin (NIM) compressed to 3.52% from 5.17% in the previous year's quarter, which had been boosted by a one-time tax refund interest. The bank maintains an exceptionally strong capital position with a CRAR of 24.63%.
முக்கிய அம்சங்கள்
Net Profit for Q3 FY26 stood at ₹1,935 crore, while 9M FY26 profit reached ₹7,570 crore including ₹1,699 crore from NSDL stake sale.Gross NPA ratio improved significantly to 2.57% from 3.57% YoY; Net NPA remains low at 0.18% with a PCR of 99.33%.Net Advances grew 15% YoY to ₹2,38,786 crore, with a retail-to-corporate mix of 71:29.Capital Adequacy Ratio (CRAR) strengthened to 24.63%, up from 21.98% in the previous year.CASA ratio stood at 44.06%, though it saw a decline from 46.35% recorded in December 2024.
👀 கவனிக்க வேண்டியவை
Investors should view the continued improvement in asset quality and robust capital adequacy as strong indicators of stability. While NIMs have normalized after previous one-offs, the bank's healthy credit growth and low Net NPA make it a solid performer in the mid-sized banking space.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
